Categorizing genetic tests to identify their ethical, legal, and social implications

American Journal of Medical Genetics - Seminars in Medical Genetics

Volumn 106, Issue 3, 2001, Pages 233-240

  Burke, Wylie ^a   Pinsky, Linda E ^a   Press, Nancy A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Ethical; Genetic counseling; Genetic test; Legal; Social implications

Indexed keywords

APOLIPOPROTEIN E; BRCA1 PROTEIN; BRCA2 PROTEIN; GENE PRODUCT; HFE PROTEIN; UNCLASSIFIED DRUG;

ALLELE; ALZHEIMER DISEASE; CLINICAL PRACTICE; GENETIC ANALYSIS; GENETIC COUNSELING; HEMOCHROMATOSIS; HUMAN; HUNTINGTON CHOREA; LEGAL ASPECT; MEDICAL DECISION MAKING; MEDICAL ETHICS; MULTIPLE ENDOCRINE NEOPLASIA; NEWBORN SCREENING; ONCOGENE; ONCOGENE RET; PHENYLKETONURIA; PRIORITY JOURNAL; REVIEW; SOCIAL ASPECT;

GENETICS AND REPRODUCTION;

BIOETHICS; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC SCREENING; GENETICS, MEDICAL; HUMANS; NONDIRECTIVE THERAPY; PREDICTIVE VALUE OF TESTS; SOCIAL VALUES;

EID: 0034770853     PISSN: 01487299     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajmg.10011     Document Type: Review

References (45)

1. Statement on use of Apolipoprotein E testing for Alzheimer disease
2. Genetic testing for cancer susceptibility. Adopted on February 20, 1996
3. Genetic counseling
4. Statement of the American Society of Human Genetics on genetic testing for breast and ovarian cancer predisposition
5. Empirical evidence that genetic counseling is directive: Where do we go from here?
6. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic
7. "First do no harm" also applies to cancer susceptibility testing
8. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. 11. BRCA1 and BRCA2
9. Hereditary hemochromatosis: Gene discovery and its implications for population-based screening
10. Contribution of different HFE genotypes to iron overload disease: A pooled analysis
11. Is non-directive genetic counselling possible?
12. Screening and treatment of newborns
13. Iron overload, public health, and genetics: Evaluating the evidence for hemochromatosis screening
14. Shattuck lecture - Medical and societal consequences of the Human Genome Project
15. Breast and ovarian cancer incidence in BRCA1-mutation carriers
16. Apolipoprotein E epsilon4 and incidence of Alzheimer disease in a community population of older persons
17. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients
18. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
19. Shared decision making in clinical medicine: Past research and future directions
20. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis
21. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer
22. Will genetics revolutionize medicine?
23. Promoting safe and effective genetic testing in the United States
24. Pitfalls of genetic testing
25. Influence of apolipoprotein E genotype on the transmission of Alzheimer disease in a community-based sample
26. Psychological aspects of genetic counseling. VII. Thoughts on directiveness
27. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing
28. Genetic testing and Alzheimer disease: Recommendations of the Stanford Program in genomics ethics, and society
29. Predisposition genetic testing for late-onset disorders in adults: A position paper of the National Society of Genetic Counselors
30. Analysis of thiopturine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia
31. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia
32. Nondirectiveness in genetic counseling: An empirical study
33. Statement on use of DNA testing for presymptomatic identification of cancer risk
34. Contesting consent: The challenge to compulsory neonatal screening for PKU
35. The clinical introduction of genetic testing for Alzheimer disease
36. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus
37. Pharmacogenetics and the practice of medicine
38. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews
39. Population-based study of risk of breast cancer in carriers of BRCA2 mutation
40. Genetics services in a social, ethical and policy context: A collaboration between consumers and providers
41. The role of beneficence in clinical genetics: Nondirective counseling reconsidered